Name | Number of supported studies | Average coverage | |
---|---|---|---|
peripheral blood | 6 studies | 23% ± 4% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
uterus | 100% | 1256.80 | 170 / 170 | 100% | 45.95 | 458 / 459 |
lung | 100% | 2177.28 | 577 / 578 | 100% | 39.98 | 1151 / 1155 |
intestine | 100% | 1226.48 | 964 / 966 | 100% | 34.30 | 525 / 527 |
thymus | 100% | 1046.24 | 651 / 653 | 99% | 29.42 | 596 / 605 |
skin | 100% | 1350.04 | 1807 / 1809 | 98% | 29.19 | 463 / 472 |
bladder | 100% | 1206.57 | 21 / 21 | 97% | 34.93 | 490 / 504 |
stomach | 98% | 841.26 | 351 / 359 | 99% | 34.67 | 284 / 286 |
breast | 100% | 1225.27 | 459 / 459 | 97% | 28.62 | 1085 / 1118 |
kidney | 100% | 1540.52 | 89 / 89 | 97% | 26.04 | 873 / 901 |
esophagus | 98% | 726.75 | 1412 / 1445 | 99% | 39.09 | 181 / 183 |
prostate | 99% | 1469.70 | 243 / 245 | 97% | 20.85 | 486 / 502 |
ovary | 96% | 576.42 | 173 / 180 | 99% | 39.12 | 426 / 430 |
pancreas | 91% | 812.56 | 300 / 328 | 97% | 45.16 | 172 / 178 |
liver | 73% | 562.07 | 164 / 226 | 94% | 27.71 | 382 / 406 |
adrenal gland | 100% | 1091.75 | 258 / 258 | 62% | 8.58 | 143 / 230 |
brain | 38% | 164.29 | 1017 / 2642 | 74% | 11.67 | 522 / 705 |
lymph node | 0% | 0 | 0 / 0 | 100% | 178.23 | 29 / 29 |
spleen | 100% | 2616.36 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 81.50 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 11.57 | 1 / 1 |
adipose | 100% | 1335.59 | 1200 / 1204 | 0% | 0 | 0 / 0 |
peripheral blood | 99% | 2346.72 | 923 / 929 | 0% | 0 | 0 / 0 |
blood vessel | 98% | 879.26 | 1310 / 1335 | 0% | 0 | 0 / 0 |
muscle | 93% | 794.31 | 745 / 803 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 89% | 13.58 | 71 / 80 |
heart | 83% | 553.13 | 712 / 861 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0006954 | Biological process | inflammatory response |
GO_0033554 | Biological process | cellular response to stress |
GO_0045063 | Biological process | T-helper 1 cell differentiation |
GO_0045087 | Biological process | innate immune response |
GO_0034097 | Biological process | response to cytokine |
GO_0007249 | Biological process | canonical NF-kappaB signal transduction |
GO_0032922 | Biological process | circadian regulation of gene expression |
GO_0071470 | Biological process | cellular response to osmotic stress |
GO_0043011 | Biological process | myeloid dendritic cell differentiation |
GO_0032688 | Biological process | negative regulation of interferon-beta production |
GO_0019882 | Biological process | antigen processing and presentation |
GO_0038061 | Biological process | non-canonical NF-kappaB signal transduction |
GO_0045892 | Biological process | negative regulation of DNA-templated transcription |
GO_0030098 | Biological process | lymphocyte differentiation |
GO_0045944 | Biological process | positive regulation of transcription by RNA polymerase II |
GO_0005813 | Cellular component | centrosome |
GO_0032991 | Cellular component | protein-containing complex |
GO_0005654 | Cellular component | nucleoplasm |
GO_0017053 | Cellular component | transcription repressor complex |
GO_0071159 | Cellular component | NF-kappaB complex |
GO_0005829 | Cellular component | cytosol |
GO_0045202 | Cellular component | synapse |
GO_0005737 | Cellular component | cytoplasm |
GO_0000785 | Cellular component | chromatin |
GO_0005634 | Cellular component | nucleus |
GO_0000978 | Molecular function | RNA polymerase II cis-regulatory region sequence-specific DNA binding |
GO_0000981 | Molecular function | DNA-binding transcription factor activity, RNA polymerase II-specific |
GO_0019901 | Molecular function | protein kinase binding |
GO_0042802 | Molecular function | identical protein binding |
GO_0005515 | Molecular function | protein binding |
Gene name | RELB |
Protein name | RELB proto-oncogene, NF-kB subunit (V-rel reticuloendotheliosis viral oncogene homolog B, nuclear factor of kappa light polypeptide gene enhancer in B-cells 3 (Avian)) RELB proto-oncogene, NF-kB subunit Transcription factor RelB (I-Rel) |
Synonyms | hCG_22137 |
Description | FUNCTION: NF-kappa-B is a pleiotropic transcription factor which is present in almost all cell types and is involved in many biological processed such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric RelB-p50 and RelB-p52 complexes are transcriptional activators. RELB neither associates with DNA nor with RELA/p65 or REL. Stimulates promoter activity in the presence of NFKB2/p49. As a member of the NUPR1/RELB/IER3 survival pathway, may provide pancreatic ductal adenocarcinoma with remarkable resistance to cell stress, such as starvation or gemcitabine treatment. Regulates the circadian clock by repressing the transcriptional activator activity of the CLOCK-BMAL1 heterodimer in a CRY1/CRY2 independent manner. Increased repression of the heterodimer is seen in the presence of NFKB2/p52. Is required for both T and B lymphocyte maturation and function . . |
Accessions | Q01201 ENST00000700471.1 A0A8V8TQY2 D6RIV7 K7ERX9 ENST00000589972.1 ENST00000509480.5 ENST00000221452.13 D6R992 ENST00000505236.2 |